Terns Pharmaceuticals, Inc. (TERN)
| Market Cap | 170.77M |
| Revenue (ttm) | 1,000,000 |
| Net Income (ttm) | -53.79M |
| Shares Out | 37.61M |
| EPS (ttm) | -2.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 116,683 |
| Open | 4.61 |
| Previous Close | 4.60 |
| Day's Range | 4.39 - 4.77 |
| 52-Week Range | 1.45 - 13.77 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 4.59 (+1.1%) |
| Earnings Date | Aug 15, 2022 |
About TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor b... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for TERN stock is "Buy." The 12-month stock price forecast is 4.59, which is an increase of 1.10% from the latest price.
News
Terns Announces $65 Million Oversubscribed Offering
FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors
FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
All You Need to Know About Terns Pharmaceuticals, Inc. (TERN) Rating Upgrade to Buy
Terns Pharmaceuticals, Inc. (TERN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL Internat...
-Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant dose-dependent effects on key target engagement biomarkers
3 Stocks Under $2 Insiders Are Aggressively Buying
US crude oil futures traded higher this morning on Thursday. Investors, meanwhile, focused on some notable insider trades.
Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022
FOSTER CITY, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer
- Dr. Russell to report to Dr. Erin Quirk, President and Head of Research & Development
Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates
-IND opened for NASH Phase 2a trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist); trial initiated with top-line data expected in second half of 2023
Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
FOSTER CITY, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...
Terns Reports Topline Results from Early-Stage NASH Study
Terns Pharmaceuticals Inc (NASDAQ: TERN) reported topline results from Part 1 of Phase 1b AVIATION Trial of TERN-201 for treating patients with non-alcoholic steatohepatitis (NASH). Part 1 of the AVIA...
Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201
FOSTER CITY, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
-Top-line data readout from TERN-201 (VAP-1 inhibitor) clinical trial in NASH expected in March 2022
Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D.
FOSTER CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference
FOSTER CITY, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
-Top-line data readout from TERN-201 (VAP-1) clinical trial in NASH expected in 1Q 2022
Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digit...
Oral presentation of data from Phase 2a LIFT Trial of TERN-101, demonstrating differentiated safety and efficacy profiles
Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experien...
FOSTER CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference
FOSTER CITY, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D.
FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...
Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201
- TERN-201 is a highly selective VAP-1 inhibitor intended to address chronic liver inflammation and fibrosis in NASH
Terns Pharmaceuticals to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...
Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
FOSTER CITY, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201
FOSTER CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist
Terns Pharmaceuticals Inc (NASDAQ: TERN) reported top-line results from the Phase 2a LIFT trial of TERN-101, a liver-distributed farnesoid X receptor (FXR) agonist for the treatment of patients with non...